Drug intelligence / Profile preview

KS104 (Klotho Sciences)

Development stage: Preclinical
Lead developer: Klotho Sciences
Modality: Small Molecules

Overview

KS104 is a small-molecule modulator of the Klotho protein currently under development by Klotho Sciences. The Klotho protein is a pleiotropic protein that acts as a circulating hormone and a membrane-bound coreceptor, playing a critical role in regulating mineral metabolism, protecting against oxidative stress, and influencing aging processes. KS104 is being investigated for its potential to treat age-related degenerative conditions, specifically Macular Degeneration (MD) and Osteoarthritis (OA). The drug is currently in the IND-enabling phase of development, aiming to leverage the protective effects of Klotho signaling to mitigate tissue degeneration associated with aging.

Targets

KL (Klotho Protein)

Beyond the preview

Go deeper on KS104 (Klotho Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS104 (Klotho Sciences).

Explore the full profile